Compare MasTec Inc (MTZ) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs ResMed Inc. — how do they compare? MasTec Inc trades at $220.47 (market cap $17.40B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: ResMed Inc. is the larger of the two by market cap, and ResMed Inc. pays a 1.16% dividend while MasTec Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MasTec Inc for 23 Days and ResMed Inc. for 51 Days on average.
| MTZ | RMD | |
|---|---|---|
Market Cap | $17.40B | $31.89B |
Volume | 1,415,821 | 618,314 |
Sector | Industrials | Health |
52-Week High | $437.51 | $277.88 |
52-Week Low | $190.08 | $182.82 |
Typical Hold Time | 23 Days | 51 Days |
Enterprise Value | $20.32B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $223.37, down 2.16% on the day, with technical indicators showing a neutral to bearish short-term bias. The company demonstrates strong fundamentals with Q1 2026 earnings beating expectations and a robust 88.9% analyst buy rating. Recent news highlights MTZ's positioning to benefit from infrastructure investment cycles, particularly in power delivery and data center markets, supported by a record $21.4 billion backlog.
The outlook remains positive given strong institutional support and infrastructure tailwinds, though premium valuation and communications segment softness pose risks. With a consensus price target of $408.58 representing 83% upside potential, the stock offers significant growth opportunity for investors comfortable with execution risks in the competitive infrastructure sector.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
